Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 17 analyst ratings
Hold
Strong Buy 12%
Buy 24%
Hold 59%
Sell 6%
Strong Sell 0%

Bulls say

Amgen has demonstrated impressive sales growth, with a 40% increase in 3Q25 compared to 3Q24, driven by strong performances across multiple therapeutic products, including significant double-digit growth in 16 of its offerings. The recent upward revision of FY25 revenue guidance to a range of $35.8-$36.6 billion from $35.0-$36.0 billion underscores the company’s robust performance and confidence in its established franchises. Furthermore, the anticipated ramp-up in Uplizna sales, with projected worldwide sales expected to reach $1.4 billion by 2027, highlights the company's strategic focus on expanding its therapeutic portfolio to capitalize on market opportunities.

Bears say

Amgen is projected to experience only modest revenue growth of approximately 1% in 2026, largely attributed to significant sales declines expected for key drugs Prolia and Xgeva, with reductions of about 28% and 39%, respectively. Additionally, while the company has a promising pipeline with emerging therapies like MariTide and olpasiran, concerns remain regarding their market viability and limited visibility into their ability to counteract the erosion of its established business. The impending loss of exclusivity for several key product franchises creates structural headwinds that may hinder Amgen's long-term growth prospects, despite the company maintaining steady near-term cash flows.

Amgen (AMGN) has been analyzed by 17 analysts, with a consensus rating of Hold. 12% of analysts recommend a Strong Buy, 24% recommend Buy, 59% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 17 analysts, Amgen (AMGN) has a Hold consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $347.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $347.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.